Drug intelligence / Profile preview

CHOP-L

Development stage
Unknown
Modality
Small Molecules, Recombinant Proteins and Enzymes
Administration
Intravenous, Oral
01

Overview

CHOP-L is a combination chemotherapy regimen, most likely referring to the standard CHOP regimen (cyclophosphamide, doxorubicin, vincristine, and prednisone/prednisolone) with the addition of L-asparaginase. This modification is commonly used in certain lymphomas such as extranodal NK/T-cell lymphoma. The mechanism of action involves multiple cytotoxic effects: - Cyclophosphamide is an alkylating agent that cross-links DNA. - Doxorubicin (hydroxydaunorubicin) intercalates into DNA and inhibits topoisomerase II. - Vincristine binds tubulin and inhibits microtubule formation. - Prednisone/prednisolone are corticosteroids that induce apoptosis in lymphoid cells. - L-asparaginase depletes asparagine, an amino acid necessary for protein synthesis in some cancer cells. This combination targets rapidly dividing malignant lymphocytes through several complementary mechanisms. It is primarily indicated for aggressive non-Hodgkin lymphoma subtypes including T-cell and NK/T-cell lymphomas[6].

02

Targets

DNAGR (Glucocorticoid receptor)TOP2A (DNA topoisomerase II)TUBB (Tubulin (alpha and beta subunits))

Beyond the preview

Go deeper on CHOP-L.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on CHOP-L.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call